PIK3C2A and lung carcinoma: Finally, Src-mediated MAPK signaling mitigates the anti-tumor activity of osimertinib in EGFR-TKI-sensitive lung cancer, and PIK3C2A mutations attenuate the effects of osimertinib in T790M-positive lung cancer.